26-Jun-2026 18:22:36
BAJAJHCAREGeneral news
BAJAJ HEALTHCARE : SEC RECOMMENDATION FOR MANUFACTURE OF CENOBAMATE TABLETS
• Bajaj Healthcare has received a recommendation from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). • The recommendation is for the grant of permission to manufacture and market Cenobamate Tablets in strengths of 12.5mg, 25mg, 50mg, 100mg, 150mg & 200mg. • Cenobamate is an antiseizure medication for partial-onset seizures in adults. • The company stated this is a significant regulatory milestone.
Bajaj Healthcare Limited
Open attachment